1. Accelerating anticancer drug development — opportunities and trade-offs. Issue 12 (December 2018) Authors: Nass, Sharyl; Rothenberg, Mace; Pentz, Rebecca; Hricak, Hedvig; Abernethy, Amy; Anderson, Kenneth; Gee, Amanda; Harvey, R.; Piantadosi, Steven; Bertagnolli, Monica; Schrag, Deborah; Schilsky, Richard Journal: Nature reviews Issue: Volume 15:Issue 12(2018) Page Start: 777 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Issue 1 (January 2017) Authors: Wilkerson, Julia; Abdallah, Kald; Hugh-Jones, Charles; Curt, Greg; Rothenberg, Mace; Simantov, Ronit; Murphy, Martin; Morrell, Joseph; Beetsch, Joel; Sargent, Daniel J; Scher, Howard I; Lebowitz, Peter; Simon, Richard; Stein, Wilfred D; Bates, Susan E; Fojo, Tito Journal: Lancet oncology Issue: Volume 18:Issue 1(2017:Jan.) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. Issue 7 (2nd July 2021) Authors: Reynolds, Kerry L; Arora, Shaily; Elayavilli, Ravikumar Komandur; Louv, William C; Schaller, Teilo H; Khandelwal, Aakanksha; Rothenberg, Mace; Khozin, Sean; Guidon, Amanda C; Dougan, Michael; Zubiri, Leyre; Petrillo, Laura; Sise, Meghan E; Villani, Alexandra-Chloe; Johnson, Douglas B; Rahma, Osam... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗